Fig. 8

Analysis of the clinical significance of IGF2BP1. A Comparison of IGF2BP1 expression in BC (n = 1109) and normal samples collected by TCGA databases (n = 113). B Comparison of IGF2BP1 in BC (n = 1109) and normal samples collected by TCGA (n = 113) and GTEX databases (n = 179). C Comparison of IGF2BP1 in BC (n = 112) and paired normal samples (n = 112) collected by TCGA databases. D The differential expression of IGF2BP1 in the T1/T2 group (n = 906) and T3/T4 group (n = 174) was collected by TCGA databases. E The differential expression of IGF2BP1 in infiltrating ductal carcinoma (n = 772) and infiltrating lobular carcinoma (n = 205) was collected by TCGA databases. Analysis of IGF2BP1 expression level in BC tissues with different PR (F), ER (G), and HER2 status (H). I The IGF2BP1 expression among PAM50 subtypes. J Representative IHC pictures of IGF2BP1 in BC tissues. K Comparison of IHC scores of IGF2BP1 between the circRRM2-low (n = 20) and circRRM2-high groups (n = 20) in patients with BC. L ROC curves based on IGF2BP1 level to discriminate between normal and cancer in patients with BC. M The KM curve for the OS in patients with BC with high vs. low IGF2BP1 expression levels. N LASSO regression analysis for screening coefficients in predicting the OS for patients with BC. O The plot of trajectories of variables for predicting the probability of the OS for patients with BC. P Nomogram for predicting the 1-, 3‐, or 5‐year OS time in patients. *P < 0.05, **P < 0.01, ***P < 0.001